Neurobiology of Aging
Volume 29, Issue 3 , Pages 348-356 , March 2008

Enhanced soluble CD40 ligand and Alzheimer's disease: Evidence of a possible pathogenetic role

  • Giovambattista Desideri

      Affiliations

    • Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, Italy
    • These authors contributed equally to this work.
    • Corresponding Author InformationCorresponding author. Tel.: +39 862 434746; fax: +39 862 434749.
    • ,
  • Francesco Cipollone

      Affiliations

    • Atherosclerosis Prevention Center and Clinical Research Center, University of Chieti “G. D’Annunzio”, Chieti, Italy
    • These authors contributed equally to this work.
    • ,
  • Stefano Necozione

      Affiliations

    • Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, Italy
    • ,
  • Carmine Marini

      Affiliations

    • Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, Italy
    • ,
  • Maria Carmela Lechiara

      Affiliations

    • Serafino Rinaldi Hospital, L’Aquila, Italy
    • ,
  • Guglielmo Taglieri

      Affiliations

    • Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, Italy
    • ,
  • Giovanni Zuliani

      Affiliations

    • Section of Internal Medicine, Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy
    • ,
  • Renato Fellin

      Affiliations

    • Section of Internal Medicine, Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Ferrara, Ferrara, Italy
    • ,
  • Andrea Mezzetti

      Affiliations

    • Atherosclerosis Prevention Center and Clinical Research Center, University of Chieti “G. D’Annunzio”, Chieti, Italy
    • ,
  • Ferdinando di Orio

      Affiliations

    • Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, Italy
    • ,
  • Claudio Ferri

      Affiliations

    • Department of Internal Medicine and Public Health, University of L’Aquila, L’Aquila, Italy

Received 22 July 2006 ,Revised 4 October 2006 ,Accepted 18 October 2006.

References 

  1. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106(8):896–899
  2. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Circulation. 1999;100:614–620
  3. Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology. 2006;67(3):441–445
  4. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging. 2000;21:153–160
  5. Calingasan NY, Erdely HA, Altar CA. Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol. Aging. 2002;23:31–39
  6. Ciabattoni, G., Porreca, E., Di Febbo, C., Di Iorio, A., Paganelli, R., Bucciarelli, T., Pescara, L., Del Re, L., Giusti, C., Falco, A., Sau, A., Patrono, C., Davi, G., 2006. Determinants of platelet activation in Alzheimer's disease. Neurobiol. Aging [January 23; Epub ahead of print].
  7. Cipollone F, Chiarelli F, Davi G, Ferri C, Desideri G, Fazia M, et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia. 2005;48:1216–1224
  8. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation. 2003;108:2776–2782
  9. Cipollone F, Mezzetti A, Porreca E, Di Febbo C, Nutini M, Fazia M, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002;106:399–402
  10. Cummings JL, Cole G. Alzheimer disease. JAMA. 2002;287:2335–2338
  11. de la Torre JC. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol. Aging. 2000;21:331–342
  12. Desideri G, Ferri C. Effects of obesity and weight loss on soluble CD40L levels. JAMA. 2003;289(14):1781–1782
  13. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2001;98:5856–5861
  14. Folstein M, Folstein S, McHugh P. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975;12:189–198
  15. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur. J. Immunol. 1995;25:1749–1754
  16. Greenwood J, Wang Y, Calder VL. Lymphocyte adhesion and transendothelial migration in the central nervous system: the role of LFA-1, ICAM-1, VLA-4 and VCAM-1. Immunology. 1995;86:408–415
  17. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 2003;348:1104–1111
  18. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–594
  19. Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol. Aging. 2000;21:289–292
  20. Kalaria RN. Microglia and Alzheimer's disease. Curr. Opin. Hematol. 1999;6:15–24
  21. Khachaturian ZS. Plundered memories. Sciences. 1997;37:20–25
  22. Li J, Zhao SP, Peng DQ, Xu ZM, Zhou HN. Early effect of pravastatin on serum soluble CD40L, matrix metalloproteinase-9, and C-reactive protein in patients with acute myocardial infarction. Clin. Chem. 2004;50:1696–1699
  23. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40–CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. U.S.A. 1997;94:1931–1936
  24. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRA work group under the auspices of Department of Health and Human Services task forces on Alzheimer's disease. Neurology. 1984;34:939–944
  25. Meda L, Cassatella MA, Szendrei GI, Otvos L, Baron P, Villalba M, et al. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature. 1995;374:647–650
  26. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412–2414
  27. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J. Am. Coll. Cardiol. 2005;46:1425–1433
  28. Reisberg B, Burns A, Brodaty H, Eastwood R, Rossor M, Sartorius N, et al. Diagnosis of Alzheimer's disease: report of an International Psychogeriatric Association Special Meeting Work Group under the cosponsorship of Alzheimer's Disease International, the European Federation of Neurological Societies, the World Health Organization, and the World Psychiatric Association. Int. Psychogeriatr. 1997;9(Suppl. 1):11–38
  29. Roman, G.C., Tatemichi, T.K., Erkinjuntti, T., Cummings, J.L., Masdeu, J.C., Garcia, J.H., Amaducci, L., Orgogozo, J.M., Brun, A., Hofman, A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–60.
  30. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am. J. Psychiatry. 1984;141:1356–1364
  31. Santilli F, Davi G, Consoli A, Cipollone F, Mezzetti A, Falco A, et al. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 2006;47:391–397
  32. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM. Soluble CD40L and cardiovascular risk in women. Circulation. 2001;104:2266–2268
  33. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS. Platelet activation in Alzheimer disease. Arch. Neurol. 1998;55:530–536
  34. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA. 1997;277:813–817
  35. Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, Browne P, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch. Neurol. 2005;62:753–757
  36. Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan M. Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res. 1998;807(1–2):110–117
  37. Tan J, Town T, Paris D, Placzek A, Parker T, Crawford F, et al. Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. J. Neuroimmunol. 1999;97:77–85
  38. Tan J, Town T, Paris D, Mori T, Suo Z, Crawford F, et al. Microglial activation resulting from CD40–CD40L interaction after beta-amyloid stimulation. Science. 1999;286:2352–2355
  39. Tan J, Town T, Suo Z, Wu Y, Song S, Kundtz A, et al. Induction of CD40 on human endothelial cells by Alzheimer's beta-amyloid peptides. Brain Res. Bull. 1999;50:143–148
  40. Town T, Tan J, Flavell RA, Mullan M. T-cells in Alzheimer's disease. Neuromol. Med. 2005;7:255–264
  41. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation. 2002;106:981–986
  42. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MMB. Silent brain infarcts and the risk of dementia and cognitive decline. N. Eng. J. Med. 2003;348:1215–1222
  43. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000;57:1439–1443

PII: S0197-4580(06)00396-4

doi: 10.1016/j.neurobiolaging.2006.10.019

Neurobiology of Aging
Volume 29, Issue 3 , Pages 348-356 , March 2008

Article Tools

* Image Usage & Resolution